Applied Therapeutics, Inc. (NASDAQ:APLT – Free Report) – Analysts at William Blair reduced their Q2 2025 earnings estimates for shares of Applied Therapeutics in a research report issued to clients and investors on Tuesday, October 22nd. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.10). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. William Blair also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.36) EPS.
Applied Therapeutics (NASDAQ:APLT – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $10.00 million.
View Our Latest Report on APLT
Applied Therapeutics Trading Down 5.5 %
NASDAQ APLT opened at $8.43 on Thursday. Applied Therapeutics has a 12 month low of $1.79 and a 12 month high of $9.39. The stock has a market cap of $963.27 million, a price-to-earnings ratio of -4.58 and a beta of 2.04. The company’s 50 day moving average is $7.19 and its two-hundred day moving average is $5.69.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Applied Therapeutics in the second quarter valued at $920,000. Bank of New York Mellon Corp purchased a new position in shares of Applied Therapeutics in the second quarter valued at $1,325,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Applied Therapeutics by 17.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock valued at $10,676,000 after purchasing an additional 333,278 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of Applied Therapeutics in the second quarter valued at $3,414,000. Finally, Algert Global LLC purchased a new position in Applied Therapeutics during the second quarter worth $110,000. 98.31% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, CEO Shoshana Shendelman sold 300,000 shares of Applied Therapeutics stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $5.98, for a total transaction of $1,794,000.00. Following the sale, the chief executive officer now owns 5,167,853 shares in the company, valued at $30,903,760.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.60% of the company’s stock.
About Applied Therapeutics
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Further Reading
- Five stocks we like better than Applied Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Texas Roadhouse Stock Steering for New Highs This Year
- Energy and Oil Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Why Are Stock Sectors Important to Successful Investing?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.